Bayer and Mammoth Biosciences to collaborate on novel gene editing technolog
- Details
- Category: Bayer
Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboration and option agreement for the use of Mammoth's CRISPR systems to develop in vivo gene-editing therapies.
Pfizer and BioNTech sign new global collaboration agreement to develop first mRNA-based shingles vaccine
- Details
- Category: Business
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.
Leiden University Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine
- Details
- Category: Business
Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with Dutch Leiden University Medical Center (LUMC) to develop and evaluate a new nasal spray corona vaccine in a clinical phase I/II study.
Pfizer and BioNTech receive U.S. FDA Emergency Use Authorization of COVID-19 vaccine booster for individuals 12 years of age and older
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 12 years of age and older. The booster dose is the same dosage strength (30-µg) as the dose approved in the primary series.
AstraZeneca and Ionis close agreement to develop and commercialise eplontersen
- Details
- Category: AstraZeneca
AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX.
The companies will jointly develop and commercialise eplontersen in the US, while AstraZeneca will develop and commercialise it in the rest of the world, except in Latin America.
Vaxzevria significantly boosted antibody levels against Omicron
- Details
- Category: AstraZeneca
AstraZeneca's Vaxzevria (ChAdOx1-S [Recombinant]) significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose booster, according to data from a new laboratory study.(1)
Neutralisation titres for Omicron were boosted following a third dose with Vaxzevria compared to titres after a second dose.(1)
European Commission grants conditional marketing authorization for Novavax COVID-19 vaccine
- Details
- Category: Business
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has granted Novavax conditional marketing authorization (CMA) for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
More Pharma News ...
- Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study
- Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
- Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
- EUR 50 million for social businesses - Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements
- Pfizer and BioNTech provide update on Omicron variant
- Roche completed the repurchase of Roche shares from Novartis
- GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease